CDMO Lotte inks commercial production deal as work on South Korean plant wraps

two jiggsaw puzzles connected with drawn hands shaking on the two puzzles
Lotte expects to kick off commercial production at its new $3.3 billion Songdo Bio Campus near Seoul next year. (tadamichi/Getty Images)

Lotte Biologics, a South Korea-headquartered CDMO established in 2022, has inked a large manufacturing deal with an unnamed pharmaceutical company as it gears up for commercial production at its new $3.3 billion Songdo Bio Campus near Seoul.

The deal marks the first for the site, which is expected to begin full-scale manufacturing next year, and calls on Lotte to produce both drug substance and drug product for the customer, the CDMO said in a Nov. 17 press release.

Although the name of the client and other details, including the value of the contract, weren’t disclosed, local publication Chosun Biz suggested that Korean compatriot Celltrion is a likely candidate. 

Lotte, meanwhile, has said it expects the new facility to help generate at least 1 trillion won ($753 million) in revenue by 2030.

“This agreement is a strong endorsement of our strategy and the confidence our customers place in Lotte Biologics,” James Park, Lotte’s co-CEO, said in a statement. “We are building a globally integrated platform designed to deliver quality, reliability and speed.”

The new facility will complement Lotte Biologics' Syracuse, New York, plant that recently completed an inspection by the FDA with zero observations, the company said. Lotte acquired that facility from Bristol Myers Squibb for $160 million in 2023.

“By combining Syracuse's proven expertise with Songdo's advanced infrastructure, we are well positioned to support our partners' success and bring life-changing medicines to patients worldwide,” said Park.

Lotte's overall Songdo campus was designed to occupy about 2.2 million square feet and feature three production plants with a total capacity of 360,000 liters, as well as essential auxiliary buildings.

Plant 1, which will provide 120,000 liters through eight 15,000-liter bioreactors, reached GMP-ready status last week, six months ahead of schedule, the company said. Lotte also held a completion ceremony for the facility this week. 

The Lotte Group, which was established in the late 1960s, is one of South Korea’s largest conglomerates, with ties to the food and beverage, retail, chemical and hotel and service sectors. 

The company’s foray into the life sciences began in 2021 after it considered taking a stake in Enzychem Lifesciences. However, that deal, fell apart and Lotte established Lotte Biologics instead, soon after buying the Syracuse facility.